{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:22:00Z","timestamp":1790018520517,"version":"4.0.1"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The expanding therapeutic landscape of inflammatory bowel disease has highlighted the need for clear and standardized drug nomenclature to support safe prescribing, pharmacovigilance, international communication, and patient understanding. The World Health Organization\u2019s international nonproprietary name system, established in 1953, assigns unique and informative names to medicines. However, the increasing number and diversity of monoclonal antibodies used in inflammatory bowel disease and other diseases have outgrown the capacity of the traditional -mab suffix to convey meaningful structural or functional distinctions. In 2021, the international nonproprietary name system was updated to introduce new suffixes, such as -tug, -bart, -ment, and -mig, that provide more precise information, although these remain unfamiliar to many clinicians. This narrative review explores how international drug naming conventions have evolved and have been applied within the context of inflammatory bowel disease, from early compounds to contemporary engineered therapies, and examines the rationale and clinical relevance of the updated naming framework. Drawing on historical and current literature, as well as policy documents from the World Health Organization\u2019s international nonproprietary name expert group, this review charts the development and successive reforms of the naming scheme. As inflammatory bowel disease therapies continue to diversify, understanding this evolving nomenclature is increasingly important for safe prescribing and effective communication.<\/jats:p>","DOI":"10.1093\/ibd\/izaf334","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T12:24:14Z","timestamp":1767443054000},"page":"1174-1182","source":"Crossref","is-referenced-by-count":1,"title":["Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-8358","authenticated-orcid":false,"given":"Michael","family":"Colwill","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospitals NHS Foundation Trust , London,","place":["United Kingdom"]},{"name":"Institute of Infection and Immunity, City St George\u2019s, University of London , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-4260","authenticated-orcid":false,"given":"Kamal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospitals NHS Foundation Trust , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-6545","authenticated-orcid":false,"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust Inflammatory Bowel Disease Unit, , Hull,","place":["United Kingdom"]},{"name":"Hull York Medical School, University of Hull , Hull,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-3400","authenticated-orcid":false,"given":"Shahida","family":"Din","sequence":"additional","affiliation":[{"name":"Edinburgh Inflammatory Bowel Diseases Unit, NHS Lothian , Edinburgh,","place":["United Kingdom"]},{"name":"Institute of Genetics and Cancer, University of Edinburgh , Edinburgh,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-2763","authenticated-orcid":false,"given":"Sailish","family":"Honap","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospitals NHS Foundation Trust , London,","place":["United Kingdom"]},{"name":"School of Immunology and Microbial Sciences, King\u2019s College London Department of Immunobiology, , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2026060404335067100_izaf334-B1","first-page":"275","article-title":"International Nonproprietary Names (INN) for pharmaceutical substances","volume":"73","author":"Kopp-Kubel","year":"1995","journal-title":"Bull World Health Organ"},{"key":"2026060404335067100_izaf334-B2","volume-title":"Sharing Clinical Research Data: Workshop Summary","author":"Institute of Medicine (US)","year":"2013"},{"key":"2026060404335067100_izaf334-B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00535-006-1995-7","article-title":"Inflammatory bowel disease: past, present, and future","volume":"42","author":"Sands","year":"2007","journal-title":"J Gastroenterol"},{"key":"2026060404335067100_izaf334-B4","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/jcm14051536","article-title":"Paradigm shift in inflammatory bowel disease management: precision medicine, artificial intelligence, and emerging therapies","volume":"14","author":"Caballero Mateos","year":"2025","journal-title":"J Clin Med"},{"key":"2026060404335067100_izaf334-B5","doi-asserted-by":"publisher","first-page":"i1518","DOI":"10.1093\/ecco-jcc\/jjae190.0963","article-title":"P0789 Combined inhibition of TL1A and integrin \u03b27 is superior to either monotherapy in mouse models of colitis and coadministration of SPY001 and SPY002 demonstrates no drug-drug effects on exposure in non-human primates","volume":"19","author":"Siegel","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026060404335067100_izaf334-B6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"key":"2026060404335067100_izaf334-B7","doi-asserted-by":"publisher","first-page":"2075078","DOI":"10.1080\/19420862.2022.2075078","article-title":"International nonproprietary names for monoclonal antibodies: an evolving nomenclature system","volume":"14","author":"Guimaraes Koch","year":"2022","journal-title":"MAbs"},{"key":"2026060404335067100_izaf334-B8","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1136\/ard-2023-224660","article-title":"Nanna Svartz (1890-1986) and the discovery of sulfasalazine","volume":"82","author":"Wollheim","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026060404335067100_izaf334-B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-198600321-00003","article-title":"Sulphasalazine: a review of 40 years\u2019 experience","volume":"32 Suppl 1","author":"Watkinson","year":"1986","journal-title":"Drugs"},{"key":"2026060404335067100_izaf334-B10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.crohns.2009.05.001","article-title":"The long journey of salicylates in ulcerative colitis: the past and the future","volume":"3","author":"Caprilli","year":"2009","journal-title":"J Crohns Colitis"},{"key":"2026060404335067100_izaf334-B11","author":"PubChem","year":"2025"},{"key":"2026060404335067100_izaf334-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rdc.2015.08.001","article-title":"The history of cortisone discovery and development","volume":"42","author":"Burns","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2026060404335067100_izaf334-B13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"2026060404335067100_izaf334-B14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute severe ulcerative colitis trials: the past, the present and the future","volume":"73","author":"Honap","year":"2024","journal-title":"Gut"},{"key":"2026060404335067100_izaf334-B15","doi-asserted-by":"publisher","first-page":"43190","DOI":"10.1021\/acsomega.2c05892","article-title":"Investigation of the influence of various functional groups on the dynamics of glucocorticoids","volume":"7","author":"Yadav","year":"2022","journal-title":"ACS Omega"},{"key":"2026060404335067100_izaf334-B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids-mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2026060404335067100_izaf334-B17","volume-title":"StatPearls","author":"Hodgens","year":"2025"},{"key":"2026060404335067100_izaf334-B18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jcyt.2021.02.114","article-title":"The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough","volume":"23","author":"Loizides","year":"2021","journal-title":"Cytotherapy"},{"key":"2026060404335067100_izaf334-B19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.biologicals.2019.05.006","article-title":"The INN global nomenclature of biological medicines: a continuous challenge","volume":"60","author":"Robertson","year":"2019","journal-title":"Biologicals"},{"key":"2026060404335067100_izaf334-B20"},{"key":"2026060404335067100_izaf334-B21"},{"key":"2026060404335067100_izaf334-B22"},{"key":"2026060404335067100_izaf334-B23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/gutjnl-2024-331927","article-title":"Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?","volume":"73","author":"Ford","year":"2024","journal-title":"Gut"},{"key":"2026060404335067100_izaf334-B24"},{"key":"2026060404335067100_izaf334-B25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1503\/cmaj.109-4864","article-title":"The art and science of naming drugs","volume":"186","author":"Collier","year":"2014","journal-title":"CMAJ"},{"key":"2026060404335067100_izaf334-B26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3389\/fphar.2018.01107","article-title":"Revisiting the role of thiopurines in inflammatory bowel disease through pharmacogenomics and use of novel methods for therapeutic drug monitoring","volume":"9","author":"Lim","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026060404335067100_izaf334-B27","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/ecco-jcc\/jjac004","article-title":"The thiopurine tale: an unexpected journey","volume":"16","author":"Crouwel","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026060404335067100_izaf334-B28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/injr.injr_13_23","article-title":"The methotrexate story: how did a cancer chemotherapeutic agent become a disease-modifying antirheumatic drug","volume":"18","author":"Malaviya","year":"2023","journal-title":"Indian J Rheumatol"},{"key":"2026060404335067100_izaf334-B29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/00003495-198937060-00004","article-title":"Muromonab CD3. a review of its pharmacology and therapeutic potential","volume":"37","author":"Todd","year":"1989","journal-title":"Drugs"},{"key":"2026060404335067100_izaf334-B30"},{"key":"2026060404335067100_izaf334-B31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/BTT.S207246","article-title":"Remicade\u00ae (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"key":"2026060404335067100_izaf334-B32","doi-asserted-by":"publisher","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2026060404335067100_izaf334-B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19420862.2015.1114320","article-title":"The INNs and outs of antibody nonproprietary names","volume":"8","author":"Jones","year":"2016","journal-title":"MAbs"},{"key":"2026060404335067100_izaf334-B34"},{"key":"2026060404335067100_izaf334-B35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/jcm14031001","article-title":"Role of mirikizumab in the treatment of inflammatory bowel disease-from bench to bedside","volume":"14","author":"Colwill","year":"2025","journal-title":"J Clin Med"},{"key":"2026060404335067100_izaf334-B36","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1080\/19420862.2017.1341029","article-title":"Changes to international nonproprietary names for antibody therapeutics 2017 and beyond: of mice, men and more","volume":"9","author":"Parren","year":"2017","journal-title":"MAbs"},{"key":"2026060404335067100_izaf334-B37"},{"key":"2026060404335067100_izaf334-B38"},{"key":"2026060404335067100_izaf334-B39"},{"key":"2026060404335067100_izaf334-B40"},{"key":"2026060404335067100_izaf334-B41"},{"key":"2026060404335067100_izaf334-B42"},{"key":"2026060404335067100_izaf334-B43"},{"key":"2026060404335067100_izaf334-B44"},{"key":"2026060404335067100_izaf334-B45","doi-asserted-by":"publisher","first-page":"i79","DOI":"10.1093\/ecco-jcc\/jjae190.0039B","article-title":"OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)","volume":"19","author":"Reinisch","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026060404335067100_izaf334-B46","author":"Sanofi"},{"key":"2026060404335067100_izaf334-B47","author":"Merck Sharp & Dohme LLC"},{"key":"2026060404335067100_izaf334-B48","author":"Merck Sharp & Dohme LLC"},{"key":"2026060404335067100_izaf334-B49","author":"Roche"},{"key":"2026060404335067100_izaf334-B50","author":"Roche"},{"key":"2026060404335067100_izaf334-B51","doi-asserted-by":"publisher","first-page":"i1618","DOI":"10.1093\/ecco-jcc\/jjae190.1022","article-title":"P0848 engineering and development of a novel bispecific antibody targeting both TL1A and \u03b14\u03b27 for the treatment of IBD","volume":"19","author":"Ran","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026060404335067100_izaf334-B52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.autrev.2018.07.014","article-title":"Bispecific antibodies: the next generation of targeted inflammatory bowel disease therapies","volume":"18","author":"Peyrin-Biroulet","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2026060404335067100_izaf334-B53","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026060404335067100_izaf334-B54","doi-asserted-by":"publisher","first-page":"2505092","DOI":"10.1080\/19420862.2025.2505092","article-title":"Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies","volume":"17","author":"Brennan","year":"2025","journal-title":"MAbs"},{"key":"2026060404335067100_izaf334-B55","doi-asserted-by":"publisher","first-page":"102596","DOI":"10.1016\/j.coph.2025.102596","article-title":"Innovative pipeline therapeutics in IBD: anti-TL1A and bispecific antibodies","volume":"86","author":"Estevinho","year":"2026","journal-title":"Curr Opin Pharmacol"},{"key":"2026060404335067100_izaf334-B56","doi-asserted-by":"publisher","first-page":"i2046","DOI":"10.1093\/ecco-jcc\/jjae190.1288","article-title":"P1114 engineering and development of a novel bispecific antibody targeting IL-23 and TL1A","volume":"19","author":"Huang","year":"2025","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1174\/66851438\/izaf334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1174\/66851438\/izaf334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:34:04Z","timestamp":1780562044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/6\/1174\/8472685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf334","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,11]]}}}